Business Wire

Tuition Hikes and International Student Visa Restrictions Fuel Demand for Investment Migration Programs

2.9.2019 19:44:00 EEST | Business Wire | Press release

Share

As global headlines are dominated by the effects of changing immigration policies in the UK and the US, there is one consequence that has gone largely unnoticed: a significant decline in international student numbers. Latest statistics show that top universities have seen international enrollment figures drop significantly in response to new restrictions on student visas in the US, uncertainty over Brexit and the rights of EU citizens in the UK, and tuition hikes in both countries.

Seeking to avoid these pitfalls, high-net-worth individuals (HNWIs) are pursuing alternative residence or citizenship rights that will allow their children to fulfil their academic aspirations without becoming entangled in risky or unpredictable visa application processes.

Dr. Juerg Steffen, CEO of investment migration firm Henley & Partners, says education is a fundamental priority for most clients. “There are many reasons for acquiring alternative citizenship or residence, but ultimately, it comes down to long-term stability and security – a classic investment hedge against potential volatility. The dramatically expanded education options that open up by having alternative citizenship or residence in a desirable location is often a decisive factor for families when they are considering making this kind of investment.”

The UK Investor Immigration Program is ideal for investors seeking to take advantage of the UK’s excellent primary, secondary, and tertiary education services. As noted by the Knight Frank Global Wealth Report, although Australia, Canada, Switzerland, the US, and a number of other countries all attract students from overseas, the UK’s private boarding schools are still seen as the gold standard by many. At the tertiary level, the Oxford and Cambridge universities are currently ranked number one and two in the world by Times Higher Education, which provides the definitive list of the world’s best universities.

Of the universities in mainland Europe, revered institutions such as Humboldt University of Berlin, Sorbonne University in Paris, and the University of Amsterdam continue to draw wealthy international students, attracted by both the peerless quality of education on offer and the experience of student life in a European capital. For investors wanting to give their children access to these kinds of opportunities, a key advantage of European universities is that fees for EU citizens are much lower than they are for non-EU citizens — up to 50% or more. For an investment of between EUR 1 million and EUR 2.15 million, Malta and Cyprus offer the most popular citizenship-by-investment programs in the EU at present.

Across the Atlantic, the US EB-5 Immigrant Investor Program is an attractive option for those who have their sights set on an American education. The program offers permanent residence in exchange for an investment of USD 500,000 to USD 1 million. The Australia Residence-by-Investment Program is another potential avenue to pursue. Overall, the country is renowned for its education system — one of many reasons it remains the top destination of choice for HNWIs looking to resettle.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Sarah Nicklin
Senior Group PR Manager
sarah.nicklin@henleyglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t

Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl

IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release

IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w

Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 23:06:00 EEST | Press release

SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in US dollars and 3 percent in constant currency compared to Q4 of the prior yea

Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 23:00:00 EEST | Press release

Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas GulfLink will immediately begin construction of its deepwater crude oil export terminal, unlock

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye